Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 1
2009 1
2010 1
2011 2
2012 3
2013 4
2014 4
2015 3
2016 1
2017 2
2019 3
2020 4
2021 6
2022 8
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Moreau P, et al. Among authors: vekemans mc. Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Lancet. 2019. PMID: 31171419 Clinical Trial.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Béné MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. Moreau P, et al. Among authors: vekemans mc. Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13. Lancet Oncol. 2021. PMID: 34529931 Clinical Trial.
COVID-19, impact on myeloma patients.
Dufour I, Raedemaeker J, Andreozzi F, Verstraete G, Bailly S, Delforge M, Storms P, Jacquy C, Van de Velde A, Mineur P, Lejeune M, Bauwens D, Van Obbergh F, Kentos A, Nguyen J, Fostier K, De Weweire A, Meuleman N, Vekemans MC. Dufour I, et al. Among authors: vekemans mc. Ann Hematol. 2020 Aug;99(8):1947-1949. doi: 10.1007/s00277-020-04147-7. Epub 2020 Jun 23. Ann Hematol. 2020. PMID: 32577846 Free PMC article. No abstract available.
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.
Delforge M, Vekemans MC, Depaus J, Meuleman N, Van de Velde A, Vande Broek I, Vandervennet S, Van Hoorenbeeck S, Moorkens E, Strens D, Diels J, Ghilotti F, Haefliger B, Dalhuisen S, Deraedt W, Anguille S. Delforge M, et al. Among authors: vekemans mc. Hemasphere. 2022 Nov 29;6(12):e813. doi: 10.1097/HS9.0000000000000813. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36479545 Free PMC article. No abstract available.
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
Stege CAM, Nasserinejad K, van der Spek E, Bilgin YM, Kentos A, Sohne M, van Kampen RJW, Ludwig I, Thielen N, Durdu-Rayman N, de Graauw NCHP, van de Donk NWCJ, de Waal EGM, Vekemans MC, Timmers GJ, van der Klift M, Soechit S, Geerts PAF, Silbermann MH, Oosterveld M, Nijhof IS, Sonneveld P, Klein SK, Levin MD, Zweegman S. Stege CAM, et al. Among authors: vekemans mc. J Clin Oncol. 2021 Sep 1;39(25):2758-2767. doi: 10.1200/JCO.20.03143. Epub 2021 May 4. J Clin Oncol. 2021. PMID: 33945289 Clinical Trial.
Recommendations on the management of multiple myeloma in 2020.
Vekemans MC, Doyen C, Caers J, Wu K, Kentos A, Mineur P, Michaux L, Delforge M, Meuleman N. Vekemans MC, et al. Acta Clin Belg. 2022 Apr;77(2):445-461. doi: 10.1080/17843286.2020.1860411. Epub 2020 Dec 23. Acta Clin Belg. 2022. PMID: 33355041 Free article.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
Groen K, Stege CAM, Nasserinejad K, de Heer K, van Kampen RJW, Leys RBL, Thielen N, Westerman M, Wu KL, Ludwig I, Issa DE, Velders GA, Vekemans MC, Timmers GJ, de Boer F, Tick LW, Verbrugge A, Buitenhuis D, Cunha SM, van der Spek E, de Waal EGM, Sohne M, Sonneveld P, Nijhof IS, Klein SK, van de Donk NWCJ, Levin MD, Ypma PF, Zweegman S. Groen K, et al. Among authors: vekemans mc. EClinicalMedicine. 2023 Aug 29;63:102167. doi: 10.1016/j.eclinm.2023.102167. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37680948 Free PMC article.
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Lecouvet FE, Vekemans MC, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, Malghem J, Wuts J, Hillengass J, Vandecaveye V, Jamar F, Gheysens O, Vande Berg BC. Lecouvet FE, et al. Among authors: vekemans mc. Skeletal Radiol. 2022 Jan;51(1):59-80. doi: 10.1007/s00256-021-03841-5. Epub 2021 Aug 7. Skeletal Radiol. 2022. PMID: 34363522 Free PMC article. Review.
The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome.
Vekemans MC, Lemmens H, Delforge M, Doyen C, Pierre P, Demuynck H, Bries G, Lemmens J, Meeus P, Straetmans N, Bauwens D, Vidrequin S, Rack K, Vandenberghe P, Wlodarska I, Michaux L. Vekemans MC, et al. Br J Haematol. 2010 Jun;149(6):901-4. doi: 10.1111/j.1365-2141.2010.08113.x. Epub 2010 Feb 9. Br J Haematol. 2010. PMID: 20148877 Free article. Review. No abstract available.
Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
Caers J, Vekemans MC, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Mineur P, Offner F, Vande Broek I, Van Droogenbroeck J, Vande Velde A, Wu KL, Delforge M, Schots R, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society. Caers J, et al. Among authors: vekemans mc. Ann Med. 2013 Sep;45(5-6):413-22. doi: 10.3109/07853890.2013.801562. Epub 2013 Jun 14. Ann Med. 2013. PMID: 23767978 Review.
40 results